Joint disease is defined as any type of injury or inflammation or disease that affects human joints. Diseases of the joints could vary from acute to exceedingly chronic, unbearably painful or simply nagging and uncomfortable. It may be confined to one joint or may affect other parts of the skeleton. It can develop at any age; however, joint diseases are more prevalent in people aged between 40 and 65. Generally, women are at higher risk of developing joint diseases than men. However, it may vary with the type of joint disease. Joint diseases can be categorized into inflammatory joint disease, non-inflammatory joint diseases, and others. In inflammatory joint disease, inflammation is principal set of symptom while in non-inflammatory joint disease, inflammation may present to some extent but it is not essential feature. Other joint diseases include congenital or hereditary abnormalities and secondary joint diseases (such as tumors of joints). Inflammatory joint diseases include bursitis, infectious arthritis, rheumatoid arthritis & allied disorders, collagen disease, and others. Non-inflammatory joint diseases include, traumatic joint diseases, and degenerative joint diseases. Treatment of joint diseases depend upon the cause and joint affected. Usually, treatment of joint diseases start with RICE (Rest, Ice, Compression, and Elevation) followed by conventional therapy, biologics, and sometimes surgery.
The global joint diseases market can be segmented based on joint disease type, treatment, and region. In terms of joint disease type, the global market can be categorized into inflammatory joint disease, non-inflammatory joint disease, and others. Based on treatment, the global joint diseases market can be classified into medication (non-steroidal anti-inflammatory drugs, analgesic, steroids, biologic therapy, and immunosuppressive drug), therapy (physiotherapy and hydrotherapy), and surgery (joint replacement surgery). Rise in incidence and prevalence of various joint diseases, increased research and development expenditure, growing awareness among people, surge in geriatric population, and high number of joint injuries contribute to the growth of the global joint diseases market. However, currently available therapeutic options are effective at managing and preventing joint disease progression, the challenges of treating the joint diseases lie in the unpredictable responses of each patient, representing one of the biggest unmet needs in the global joint diseases market.
Geographically, the global joint diseases market can be segmented into five regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is anticipated to dominate the market, followed by Europe. High incidence of joint diseases, rise in geriatric population, growing awareness among people, surge in research and development expenditure, strong clinical pipeline, and well-established health care infrastructure propel the joint diseases market in North America. The market in Asia Pacific is anticipated to expand at a high CAGR during the forecast period. This is attributed to large patient base, increase in government initiatives, and developing health care infrastructure in India and China. The market in Latin America and Middle East & Africa is anticipated to grow during the forecast period, owing to rise in investments by key players in these regions and increase in prevalence of joint diseases.
Leading players in the global joint diseases market include AbbVie, Pfizer Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., GlaxoSmithKline, AstraZeneca plc, Astellas Pharma, Johnson and Johnson, Amgen, Novartis International AG, Sanofi SA, and Daiiachi Sankyo.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.